Hemab Therapeutics (NASDAQ:COAG) Trading Up 5.8% – Time to Buy?

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG)’s share price traded up 5.8% during mid-day trading on Wednesday . The company traded as high as $33.63 and last traded at $33.32. Approximately 61,732 shares changed hands during trading, a decline of 77% from the average session volume of 265,036 shares. The stock had previously closed at $31.49.

Analyst Upgrades and Downgrades

COAG has been the topic of several research analyst reports. Wall Street Zen raised shares of Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th. Wedbush initiated coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They issued an “outperform” rating and a $42.00 price target for the company. Zacks Research raised shares of Hemab Therapeutics to a “hold” rating in a research report on Wednesday, May 27th. Evercore began coverage on Hemab Therapeutics in a research report on Tuesday, May 26th. They issued an “outperform” rating and a $50.00 target price for the company. Finally, Jefferies Financial Group started coverage on Hemab Therapeutics in a research note on Tuesday, May 26th. They set a “buy” rating and a $39.00 price target on the stock. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Hemab Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $41.40.

Hemab Therapeutics Stock Performance

The company has a market cap of $1.77 billion and a price-to-earnings ratio of -1.58. The stock has a fifty day simple moving average of $28.32.

Hemab Therapeutics (NASDAQ:COAG) last posted its quarterly earnings data on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Insider Transactions at Hemab Therapeutics

In other Hemab Therapeutics news, major shareholder Ra Capital Management, L.P. bought 61,523 shares of the business’s stock in a transaction dated Tuesday, June 16th. The shares were purchased at an average price of $24.98 per share, for a total transaction of $1,536,844.54. Following the purchase, the insider directly owned 6,444,637 shares of the company’s stock, valued at approximately $160,987,032.26. This represents a 0.96% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders have bought 2,970,541 shares of company stock valued at $55,459,603.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.